Search Results

You are looking at 181 - 190 of 383 items for :

  • "Neutropenia" x
  • Refine by Access: All x
Clear All
Full access

Brentuximab in the Treatment of CD30-Positive Enteropathy-Associated T-Cell Lymphoma

Waleed F. Khalaf, Meghan E. Caldwell, and Nishitha Reddy

his baseline grade 2 neuropathy. He developed mild leukopenia without neutropenia. At his 9-month follow-up, the patient continued to show disease remission. Discussion EATL is a rare gastrointestinal lymphoma that accounts for fewer than 1% of

Full access

New Developments in the Treatment of Castration-Resistant Prostate Cancer

Celestia S. Higano

than those in the mitoxantrone group (57% vs 39%). The most common significant adverse events (≥ grade 3) for cabazitaxel were neutropenia and diarrhea. “Because of the toxicity, some people have not been too enthused about using cabazitaxel,” stated

Full access

Is Observation Dead in Follicular Lymphoma? Still Appropriate

Caron A. Jacobson and Arnold S. Freedman

deterioration in their mental adjustment to, or ability to cope with, their illness. No difference in histologic transformation or OS was observed. Finally, 12 grade 3/4 adverse events were seen in the patients who received rituximab, including neutropenia

Full access

NCCN Guidelines® Insights: Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma, Version 3.2022

Featured Updates to the NCCN Guidelines

William G. Wierda, Jennifer Brown, Jeremy S. Abramson, Farrukh Awan, Syed F. Bilgrami, Greg Bociek, Danielle Brander, Asher A. Chanan-Khan, Steve E. Coutre, Randall S. Davis, Herbert Eradat, Christopher D. Fletcher, Sameh Gaballa, Armin Ghobadi, Muhammad Saad Hamid, Francisco Hernandez-Ilizaliturri, Brian Hill, Paul Kaesberg, Manali Kamdar, Lawrence D. Kaplan, Nadia Khan, Thomas J. Kipps, Shuo Ma, Anthony Mato, Claudio Mosse, Stephen Schuster, Tanya Siddiqi, Deborah M. Stephens, Chaitra Ujjani, Nina Wagner-Johnston, Jennifer A. Woyach, J. Christine Ye, Mary A. Dwyer, and Hema Sundar

, opportunistic infections, and febrile neutropenia. NCCN Recommendations Preferred Regimens Acalabrutinib, ibrutinib, and VenR are included with a category 1 recommendation, 20 – 22 , 36 zanubrutinib is included with a category 2A recommendation, 31 and

Full access

Brentuximab Vedotin in Patients With Relapsed HIV-Related Lymphoma

Mitul Gandhi and Adam Petrich

complete response. Treatment was complicated by reversible grade 2 neuropathy and grade 2 neutropenia, neither of which required dose delay or reduction. As of most recent follow-up, he had completed 8 cycles of therapy with durable CR. He is being

Full access

Novel Systemic Therapies for Small Cell Lung Cancer

Charles M. Rudin, Christine L. Hann, Craig D. Peacock, and D. Neil Watkins

risk of severe neutropenia of irinotecan . J Clin Oncol 2004 ; 22 : 1382 – 1388 . 28. Hanna N Bunn PA Jr Langer C . Randomized phase III trial comparing irinotecan/cisplatin with etoposide/cisplatin in patients with previously untreated

Full access

Supportive Therapies in Multiple Myeloma

Charise Gleason, Ajay Nooka, and Sagar Lonial

granulocyte-colony stimulating factor be used in multiple myeloma patients developing neutropenia under lenalidomide-based therapy? Br J Haematol 2008 ; 140 : 324 – 326 . 24 Katodritou E Verrou E Hadjiaggelidou C . Erythopoiesis stimulating

Full access

Reassessing the Standard of Care in Indolent Lymphoma: A Clinical Update to Improve Clinical Practice

Mathias Rummel

caused by infections. Grade 3 or higher toxicities included neutropenia (n = 27), thrombocytopenia (n = 7), and pneumonia (n = 6), including 2 patients who died of non– Pneumocystis carinii pneumonia, suggesting that the risk for toxicities associated

Full access

Fixed-Duration Versus Until Disease Progression: How Long Should Initial Treatment of Multiple Myeloma Last?

Yvonne A. Efebera and Nina Shah

maintenance experienced grade ≥3 neutropenia and 58% had grade ≥3 hematologic toxicity compared with 22% randomized to placebo. A meta-analysis from McCarthy et al 4 demonstrated that nearly 30% of patients had treatment-emergent adverse events, resulting in

Full access

Optimizing First-Line Therapy for Follicular Lymphoma: Is It Time for Chemotherapy-Free Approaches?

Richard I. Fisher

/chemotherapy arm experienced more neutropenia and fever; however, overall, treatment discontinuations were similar in both arms: 69% of patients on the R 2 arm and 71% of those on the rituximab/chemotherapy arm completed treatment. 13 Final data showed that R 2